Absence of Growth Retardation in Children With Perennial Allergic Rhinitis After One Year of Treatment With Mometasone Furoate Aqueous Nasal Spray

• Published in: Pediatrics (Evanston) 2000-02, Vol.105 (2), p.e22-e22
• Main Authors: Schenkel, Eric J, Skoner, David P, Bronsky, Edwin A, Miller, S. David, Pearlman, David S, Rooklin, Anthony, Rosen, James P, Ruff, Michael E, Vandewalker, Mark L, Wanderer, Alan, Damaraju, Chandrasekharrao V, Nolop, Keith B, Mesarina-Wicki, Barbara
• Format: Article
• Language: English
• Subjects: Administration, Intranasal; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - therapeutic use; Child; Double-Blind Method; Female; Glucocorticoids; Growth - drug effects; Growth Disorders - chemically induced; Humans; Male; Mometasone Furoate; Pediatrics; Pregnadienediols - adverse effects; Pregnadienediols - therapeutic use; Rhinitis, Allergic, Perennial - drug therapy
• ISSN: 0031-4005; 1098-4275
• DOI: 10.1542/peds.105.2.e22

Intranasal corticosteroids are used widely for the treatment of allergic rhinitis because they are effective and well tolerated. However, their potential to suppress growth of pediatric subjects with allergic rhinitis continues to be a concern, particularly in light of reports of growth suppression after treatment with intranasal beclomethasone dipropionate or intranasal budesonide (see the article by Skoner et al in this month's issue). A 1-year study of prepubertal patients between 3 and 9 years of age with perennial allergic rhinitis was conducted to assess the effects on growth of mometasone furoate aqueous nasal spray (MFNS), a new once-daily (QD) intranasal corticosteroid with negligible bioavailability. This was a randomized, placebo-controlled, double-blind, multicenter study. Ninety-eight subjects were randomized to treatment with either MFNS 100 microg QD or placebo for 1 year. Each subject's height was required to be between the 5th and 95th percentile at baseline, and skeletal age at screening was required to be within 2 years of chronological age, as determined by left wrist x-rays. Washout periods for medications that affect either childhood growth or allergic rhinitis symptoms were established based on estimated period of effect, and these medications were prohibited during the study. However, short courses of either oral prednisone lasting no longer than 7 days or low-potency topical dermatologic corticosteroids lasting no longer than 10 days were permitted if necessary. Height was measured with a calibrated stadiometer at baseline and at 4, 8, 12, 26, 39, and 52 weeks, and the primary safety variable was the change in standing height. The rate of growth was also calculated for each subject as the slope (linear regression) of the change in height from baseline using data from all visits of subjects who had at least 2 visits. Hypothalamic-pituitary-adrenocortical- (HPA)-axis function was assessed via cosyntropin stimulation testing at baseline and at 26 and 52 weeks. All analyses were based on all randomized subjects (intent-to-treat principle). The change from baseline in standing height was analyzed by a 2-way analysis of variance that extracted sources of variation attributable to treatment, center, and treatment-by-center interaction. Demographic characteristics were similar at baseline. Eighty-two subjects completed the study (42 in the MFNS group and 40 in the placebo group), and 93% of subjects achieved at least 80% compliance with th